Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depression Treatment and Aβ Dynamics (ABD Study)
NCT05004987Phase 4Recruiting
- Sponsor
- NYU Langone Health
- Start
- Feb 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of escitalopram in major depressive disorder (MDD), sponsored by NYU Langone Health. Started Feb 2022; status: recruiting.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05004987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004987.